Mastering challenges in iPSC-derived allogeneic cell drug product manufacturing

Your details / あなたの詳細

Date and time

Wednesday

May

09:00 CEST

Confirm sign-up

About Cellistic®

Cellistic specializes in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology using their Pulse™ and Echo™ Platform. Its focus and expertise in iPSC reprogramming, gene editing using its proprietary STAR-CRISPRTM technology and differentiation development, positions the company to be the partner of choice for innovative cell therapy developers to advance into clinic. Leveraging 15 years scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cell therapies.

For more information, visit www.cellistic.com.

Presentation by
Peter Jaehn, PhD
VP Business Development Europe & Asia Pacific

Duration
50 minutes

Key Takeaways for You:

Scalability: Discover how the integration of Cellistic’s STAR-CRISPR™, Pulse™, and Echo™ platforms enables seamless scalability in cell therapy development—from initial concept to commercial drug products—while ensuring safe and reliable outcomes at every stage.
Cost Efficiency: Learn how these platforms work together to reduce both time and resource expenditures, streamlining development through standardized workflows, automation and expert guidance.
Safety and Compliance: Gain insight into the rigorous safety measures and quality controls Cellistic employs to ensure GMP compliance while developing product-specific, gene-edited master cell banks (MCBs) and managing the entire production process—from material sourcing to final cell therapy product delivery.